Ocugen, Inc. advances gene therapy platform as CEO and EVP present at global biotech events

Ocugen, Inc. advances gene therapy platform as CEO and EVP present at global biotech events
Ocugen, Inc. plans gene therapy update

Ocugen, Inc. announced that CEO Dr. Shankar Musunuri and Abhi Gupta, Executive Vice President of Commercial and Business Development, will present at international biotech conferences on April 28.

The company plans to share updates on its gene therapy platform and detail progress towards its initial Biologics License Application (BLA) submission and subsequent commercialization strategy. The participation in prominent industry events signals Ocugen, Inc.'s ongoing commitment to advancing next-generation therapies and expanding its commercial reach.

Ocugen, Inc. has previously focused on developing gene therapies targeting hundreds of mutations to address a global vision loss burden estimated at $132 billion, according to company disclosures. The firm has also credited retinal surgeons for clinical progress in modifier gene therapy aimed at major blindness diseases, as noted in prior reports. These initiatives form the foundation for Ocugen's ongoing therapeutic and commercial development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.